𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A combined group treatment for nightmares and insomnia in combat veterans: A pilot study

✍ Scribed by Leslie M. Swanson; Todd K. Favorite; Elizabeth Horin; J. Todd Arnedt

Publisher
Springer
Year
2009
Tongue
English
Weight
98 KB
Volume
22
Category
Article
ISSN
0894-9867

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Insomnia and nightmares are hallmarks of posttraumatic stress disorder (PTSD). Sleep disturbances in PTSD negatively impact clinical course and functioning. In this open clinical trial, the preliminary effects of a combined treatment for insomnia and nightmares in combat veterans with PTSD were assessed. Ten combat veterans participated in a 10‐session group treatment combining cognitive–behavioral therapy for insomnia with exposure, rescripting, and relaxation therapy. Participants maintained daily sleep and dream diaries and completed self‐report measures of sleep quality and PTSD symptoms pre‐ and posttreatment. Participants reported improvements in sleep and nightmares following treatment. Future research using controlled designs to evaluate this treatment is warranted.

📜 SIMILAR VOLUMES

A new effective treatment for indolent l
A new effective treatment for indolent lymphoma: a pilot study with fludarabine, idarubicin and prednisone combination (FLIDA)
✍ F. Caracciolo; E. Capochiani; F. Papineschi; M. Petrini 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB

The management of indolent lymphomas is still controversial. Intensive therapies may improve remission rate but in association with toxicity. Fludarabine and idarubicin are very active drugs in indolent lymphomas. This pilot trial was designed to evaluate the efficacy of a regimen comprising fludara

Adriamycin in combination for the treatm
Adriamycin in combination for the treatment of breast cancer. A southwest oncology group study
✍ Dr. B. Tranum; B. Hoogstraten; A. Kennedy; C. B. Vaughn; B. Samal; T. Thigpen; S 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c

A pilot study using nabilone for symptom
A pilot study using nabilone for symptomatic treatment in Huntington's disease
✍ Adrienne Curtis; Ian Mitchell; Smitaa Patel; Natalie Ives; Hugh Rickards 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract Pilot study of nabilone in Huntington's disease (HD). Double‐blind, placebo‐controlled, cross‐over study of nabilone versus placebo. Primary outcome, Unified Huntington's Disease Rating Scale (UHDRS) total motor score. Secondary measures: UHDRS subsections for chorea, cognition and beha

Atomoxetine for the treatment of executi
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study
✍ Laura Marsh; Kevin Biglan; Melissa Gerstenhaber; James R. Williams 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 321 KB 👁 1 views

## Abstract Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention defi

Open-label pilot study of levetiracetam
Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease
✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

Treatment with pegylated interferon and
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study
✍ Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR). In a noncontrolled multicenter trial, 122 treatment-naive patients received 1.5 mug/kg pegylated interferon alf